Ginkgo Bioworks Stock Prediction and Forecast [DNA]
1 extracted signal · 1 resolved · 0 still active
StockInvest.usIndependent analyst profile- Source published
- 07 Aug 2025, 23:40 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
![Video preview for Ginkgo Bioworks Stock Prediction and Forecast [DNA]](https://i.ytimg.com/vi/1k2RUNjludU/hqdefault.jpg)
AI-generated source summary
The analysis for Ginkgo Bioworks (DNA) stock shows a buy signal from June 9, 2025, score of 2.87. Past performance indicates a 71.68% gain over 42 days, with an average daily gain of 1.71%. Short-term trend bullish. 79% change over the next 3 months, potential returns of 50% to 113%. An average return of 12.85% expected over 12 months. range of $7.05 to $19.59. The last trading day reports a 3.58% decrease at $13.46, fluctuating 8.79% between $13.13 and $14.28. Volume rose. 52 week low to $5.00 and high of $16.85. The price is 20.12% the 52-week high. Analysts rate the stock strong sell. Last transactions of Coen Steven P. show a 57.53 insider power. Volume rose on falling prices. Support identified at $13.36 and $11.50, with resistance at $13.96. A suggested stop-loss at $12.84.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
StockInvest.us
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.
